ANKET

Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022

November 4, 2022

Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric Vivier...

Innate Pharma reports first half 2022 financial results and business update

September 15, 2022

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on...

IPH6401, NK-cell engager

What is IPH6401/SAR445514?

IPH6401/SAR445514 (SAR’514) is a trifunctional anti-BCMA NKp46/CD16 NK cell engager using Sanofi’s proprietary CROSSODILE^® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format.

Mechanism of action

It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Read more about IPH6401, NK-cell engager

Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022

Innate Pharma reports first half 2022 financial results and business update

IPH6401, NK-cell engager

What is IPH6401/SAR445514?

Mechanism of action

Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022

Second Innate Pharma NK Cell Engager Selected by Sanofi as drug candidate for development

Innate Pharma reports First Quarter 2022 financial results and business update

Innate Pharma reports Full Year 2021 financial results and business update

First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers

Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress

Innate Pharma Third Quarter 2021 Report